Cingulate Inc (CING) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.24 (+1.75%), Market cap $0.06B, 52-week low–high $3.33 ~ $11.66.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Financial statements, price targets, institutional (13F) holdings and related news for Cingulate Inc are updated in real time on BlackAll Trade.
Cingulate Inc trades at $5.24 (+1.75%). Real-time quotes and charts are available on BlackAll Trade.
Cingulate Inc has a market cap of about $0.06B.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxie